JP2014509662A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509662A5 JP2014509662A5 JP2014502901A JP2014502901A JP2014509662A5 JP 2014509662 A5 JP2014509662 A5 JP 2014509662A5 JP 2014502901 A JP2014502901 A JP 2014502901A JP 2014502901 A JP2014502901 A JP 2014502901A JP 2014509662 A5 JP2014509662 A5 JP 2014509662A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- monoclonal antibody
- use according
- skin inflammation
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 102000005614 monoclonal antibodies Human genes 0.000 claims 7
- 108010045030 monoclonal antibodies Proteins 0.000 claims 7
- 201000004624 dermatitis Diseases 0.000 claims 6
- 102000004965 antibodies Human genes 0.000 claims 4
- 108090001123 antibodies Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 206010000496 Acne Diseases 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000004681 psoriasis Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 102000004125 Interleukin-1alpha Human genes 0.000 claims 1
- 108010082786 Interleukin-1alpha Proteins 0.000 claims 1
- 230000000295 complement Effects 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Claims (15)
- 皮膚炎症治療用薬剤の製造における、ＩＬ−１αに選択的に結合する薬剤の使用。
- 請求項１に記載の使用において、前記薬剤が、抗−ＩＬ−１α抗体であることを特徴とする使用。
- 請求項２に記載の使用において、前記抗−ＩＬ−１α抗体が、モノクローナル抗体であることを特徴とする使用。
- 請求項３に記載の使用において、前記モノクローナル抗体が、ＩｇＧ１であることを特徴とする使用。
- 請求項３に記載の使用において、前記モノクローナル抗体が、ＭＡＢｐ１の相補性決定領域を含むことを特徴とする使用。
- 請求項３に記載の使用において、前記モノクローナル抗体が、ＭＡＢｐ１であることを特徴とする使用。
- 請求項１に記載の使用において、前記皮膚炎症が、尋常性座瘡に関連することを特徴とする使用。
- 請求項１に記載の使用において、前記皮膚炎症が、尋常性乾癬に関連することを特徴とする使用。
- 被験体における皮膚炎症を治療するための医薬組成物であり、前記医薬組成物が、ＩＬ−１αに選択的に結合する薬剤を含むことを特徴とする医薬組成物。
- 請求項９に記載の医薬組成物において、前記薬剤が、抗−ＩＬ−１α抗体であることを特徴とする医薬組成物。
- 請求項１０に記載の医薬組成物において、前記抗−ＩＬ−１α抗体が、モノクローナル抗体であることを特徴とする医薬組成物。
- 請求項１１に記載の医薬組成物において、前記モノクローナル抗体が、ＭＡＢｐ１の相補性決定領域を含むことを特徴とする医薬組成物。
- 請求項１２に記載の医薬組成物において、前記モノクローナル抗体が、ＭＡＢｐ１であることを特徴とする医薬組成物。
- 請求項９に記載の医薬組成物において、前記皮膚炎症が、尋常性座瘡に関連することを特徴とする医薬組成物。
- 請求項９に記載の医薬組成物において、前記皮膚炎症が、尋常性乾癬に関連することを特徴とする医薬組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161470538P | 2011-04-01 | 2011-04-01 | |
| US61/470,538 | 2011-04-01 | ||
| PCT/US2012/031803 WO2012135812A2 (en) | 2011-04-01 | 2012-04-02 | Treatment for dermatological pathologies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016145710A Division JP6453278B2 (ja) | 2011-04-01 | 2016-07-25 | 皮膚科的病理の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014509662A JP2014509662A (ja) | 2014-04-21 |
| JP2014509662A5 true JP2014509662A5 (ja) | 2015-05-21 |
| JP6062918B2 JP6062918B2 (ja) | 2017-01-18 |
Family
ID=46927554
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014502901A Active JP6062918B2 (ja) | 2011-04-01 | 2012-04-02 | 皮膚科的病理の治療 |
| JP2016145710A Active JP6453278B2 (ja) | 2011-04-01 | 2016-07-25 | 皮膚科的病理の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016145710A Active JP6453278B2 (ja) | 2011-04-01 | 2016-07-25 | 皮膚科的病理の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20120251548A1 (ja) |
| EP (2) | EP3417879A1 (ja) |
| JP (2) | JP6062918B2 (ja) |
| KR (3) | KR102326482B1 (ja) |
| CN (2) | CN103442733A (ja) |
| AU (2) | AU2012236106B2 (ja) |
| CA (1) | CA2831126C (ja) |
| DK (1) | DK2694107T3 (ja) |
| ES (1) | ES2697056T3 (ja) |
| PT (1) | PT2694107T (ja) |
| WO (1) | WO2012135812A2 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2582391T (pt) | 2010-06-18 | 2019-01-11 | Xbiotech Inc | Tratamento da artrite |
| DK2608808T3 (en) | 2010-08-23 | 2017-04-24 | Xbiotech Inc | TREATMENT OF NEOPLASTIC DISEASES |
| US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
| US20120251548A1 (en) * | 2011-04-01 | 2012-10-04 | Xbiotech, Inc. | Treatment of Dermatological Pathologies |
| KR102039198B1 (ko) | 2011-09-23 | 2019-10-31 | 엑스바이오테크, 인크. | 악액질 치료법 |
| US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
| CN104684581A (zh) * | 2012-10-04 | 2015-06-03 | 埃克斯生物科技公司 | 精神病症的治疗 |
| JP7145162B2 (ja) | 2017-02-16 | 2022-09-30 | ヤンセン バイオテク，インコーポレイテッド | 化膿性汗腺炎の処置 |
| MX2022012967A (es) * | 2020-04-16 | 2023-01-18 | Janssen Biotech Inc | Tratamiento de la hidradenitis supurativa. |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| JPH08502300A (ja) | 1992-10-14 | 1996-03-12 | スターリング ウィンスロップ アイエヌシー． | 治療および診断像形成組成物および方法 |
| US5959085A (en) * | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| GB9405021D0 (en) | 1994-03-15 | 1994-04-27 | Unilever Plc | Skin treatment composition |
| US5945576A (en) * | 1996-04-05 | 1999-08-31 | Brigham & Women's Hospital, Inc. | Mouse model of psoriasis |
| WO2002033094A1 (fr) | 2000-10-19 | 2002-04-25 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps inhibant l'activite vplf |
| JP4450644B2 (ja) | 2003-03-03 | 2010-04-14 | 日本化薬株式会社 | Ａｍｆ類を有効成分とする医薬製剤 |
| WO2006001967A2 (en) | 2004-05-25 | 2006-01-05 | Sloan-Kettering Institute For Cancer Research | Migrastatin analogs in the treatment of cancer |
| US20050276807A1 (en) * | 2004-06-15 | 2005-12-15 | Advanced Biotherapy, Inc. | Treatment of acne |
| US20090215992A1 (en) | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| RS53168B (en) | 2006-05-30 | 2014-06-30 | Genentech Inc. | Antibodies and Immunoconjugates and Their Use |
| WO2008082651A2 (en) * | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Dual-specific il-1a/ il-1b antibodies |
| PL2285409T3 (pl) * | 2008-05-30 | 2016-10-31 | Przeciwciała il-1 alfa | |
| WO2010030979A2 (en) * | 2008-09-12 | 2010-03-18 | Xbiotech, Inc. | Targeting pathogenic monocytes |
| EP2391652A4 (en) * | 2009-01-29 | 2013-01-02 | Abbott Lab | IL-1 BINDING PROTEINS |
| RU2013115927A (ru) * | 2010-09-10 | 2014-10-20 | Апексиджен, Инк. | АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ |
| US20120251548A1 (en) * | 2011-04-01 | 2012-10-04 | Xbiotech, Inc. | Treatment of Dermatological Pathologies |
| JP5812669B2 (ja) | 2011-04-27 | 2015-11-17 | キヤノン株式会社 | 画像処理装置および画像処理方法およびコンピュータプログラム。 |
-
2012
- 2012-04-02 US US13/437,159 patent/US20120251548A1/en not_active Abandoned
- 2012-04-02 PT PT12765366T patent/PT2694107T/pt unknown
- 2012-04-02 CN CN2012800140133A patent/CN103442733A/zh active Pending
- 2012-04-02 WO PCT/US2012/031803 patent/WO2012135812A2/en unknown
- 2012-04-02 JP JP2014502901A patent/JP6062918B2/ja active Active
- 2012-04-02 KR KR1020207036672A patent/KR102326482B1/ko active IP Right Grant
- 2012-04-02 EP EP18186590.8A patent/EP3417879A1/en active Pending
- 2012-04-02 AU AU2012236106A patent/AU2012236106B2/en active Active
- 2012-04-02 CA CA2831126A patent/CA2831126C/en active Active
- 2012-04-02 ES ES12765366T patent/ES2697056T3/es active Active
- 2012-04-02 KR KR1020197021295A patent/KR20190090046A/ko active Application Filing
- 2012-04-02 CN CN201910233038.6A patent/CN110201157A/zh active Pending
- 2012-04-02 DK DK12765366.5T patent/DK2694107T3/en active
- 2012-04-02 KR KR1020137028813A patent/KR102004554B1/ko active IP Right Grant
- 2012-04-02 EP EP12765366.5A patent/EP2694107B1/en active Active
-
2016
- 2016-07-25 JP JP2016145710A patent/JP6453278B2/ja active Active
- 2016-08-31 US US15/252,477 patent/US9902769B2/en active Active
-
2017
- 2017-02-22 AU AU2017201201A patent/AU2017201201B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509662A5 (ja) | ||
| NZ719368A (en) | Combination therapy of antibodies against human csf-1r and uses thereof | |
| WO2011088120A8 (en) | Antibody formulation and therapeutic regimens | |
| EP3501546A3 (de) | Cystein-wirkstoff konjugate und ihre verwendung | |
| PH12019500441A1 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| BR112013002167A2 (pt) | anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação | |
| RU2018145985A (ru) | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| NZ703481A (en) | Cd37-binding molecules and immunoconjugates thereof | |
| IL236892B (en) | A combination of an immunoconjugate and an antibody for use in medical treatment, a pharmaceutical preparation and a kit containing it | |
| DOP2012000299A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| NZ630363A (en) | Anti-kit antibodies and uses thereof | |
| MX2018001263A (es) | Nueva combinacion para el uso en el tratamiento del cancer. | |
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| JP2010222367A5 (ja) | ||
| BR112014019116A2 (pt) | Kit, composição farmacêutica, moléculas de anticorpo biespecífico, métodos de tratamento de uma doença e de produção de uma molécula de anticorpo biespecífico, anticorpo biespecífico, vetor e célula hospedeira | |
| HK1200187A1 (en) | Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient | |
| WO2014012094A3 (en) | Tetracycline compounds for treating neurodegenerative disorders | |
| NZ595189A (en) | Combination therapy with thiocolchicine derivatives | |
| JP2015531396A5 (ja) | ||
| PH12015500746A1 (en) | Benzamides | |
| JP2015530399A5 (ja) | ||
| NZ631543A (en) | Antibodies to bradykinin b1 receptor ligands | |
| WO2012135812A3 (en) | Treatment for dermatological pathologies | |
| EA201690321A1 (ru) | Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей |